Dasatinib (Bristol-Myers Squibb) is a short-acting inhibitor of multiple tyrosine kinases which is used orally in treatment of chronic myeloid leukemia, Philadelphia-chromosome positive acute Lymphoblastic leukemia (ALL), solid tumors and systemic mastocytosis [1]. Despite acceptable safety profile of dasatinib, cutaneous adverse reactions including xerosis, keratosis pilaris, pruritus, maculopapular/exfoliative rashes, edema, alopecia may limit its use in crucial conditions [2]. In case of drug-related cutaneous rashes, the primary approach is withdrawal of the culprit agent and introduction of supportive treatment.
Read Full Article
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου